hit counter
Biogen Inc. (BIIB) Stock News Sentiment & Price - Sentifly
BIIB - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Biogen Inc. (BIIB)

USA
Biotechnology
NASDAQ
BIIB Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
BIIB Latest news
Invezz
Positive
Is it safe to buy Biogen stock after boosting guidance ahead of Street forecasts?
3 hours ago

On Wednesday, Biogen Inc. (NASDAQ:BIIB) shares edged slightly higher after announcing its most recent quarterly results. The company reported better-than-expected fiscal Q3 revenue and earnings whilst also boosting its full-year 2021 guidance.

Seeking Alpha
Neutral
Biogen Inc. (BIIB) CEO Michel Vounatsos on Q3 2021 Results - Earnings Call Transcript
6 hours ago

Biogen Inc. (BIIB) CEO Michel Vounatsos on Q3 2021 Results - Earnings Call Transcript

Zacks Investment Research
Positive
Sage, Biogen Plan to File Zuranolone NDA for MDD in 2022
7 hours ago

Sage (SAGE) and partner Biogen are looking to get approval for zuranolone as an oral treatment for major depressive disorder. They will start rolling submission of an NDA in early 2022 for the candidate.

Zacks Investment Research
Positive
Biogen (BIIB) Q3 Earnings Top, Aduhelm Sales Negligible
8 hours ago

Biogen (BIIB) beats third-quarter estimates for both earnings and sales and ups its financial guidance for 2021.

Benzinga
Positive
Abbot Labs and Biogen Outshine Novavax in the Health Care Sector
9 hours ago

Just before Tuesday's close, Netflix (NASDAQ: NFLX) reported better-than-expected earnings by adding 4.4 million subscribers in the third quarter. The company cited a robust slate of content including the hit Korean television show “Squid Game,” which helped bring in new subscribers.

Zacks Investment Research
Positive
Biogen Inc. (BIIB) Q3 Earnings and Revenues Surpass Estimates
9 hours ago

Biogen Inc. (BIIB) delivered earnings and revenue surprises of 14.94% and 3.82%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Forbes
Positive
Will Biogen Stock Rise After The Recent 6% Fall?
11 hours ago

The stock price of Biogen reached a 52-week high of $468 this June before a sell-off drove the stock price down over 40% to its current level of around $266. The stock decline was partly driven by pessimism surrounding the Aduhelm launch, as we have discussed in our updates further below.

Benzinga
Positive
Biogen Posts Just $300K Sales From Aduhelm In Q3, Though Earnings Beat Estimates
11 hours ago

Biogen Inc (NASDAQ: BIIB) has posted Q3 adjusted EPS of $4.77 ahead of the consensus estimate of $4.11, but quarterly profit fell around 53% Y/Y to $329.2 million on the continued competition for Company's flagship product, Tecfidera, a multiple sclerosis drug. Sales of $2.8 billion came in slightly above the expected $2.7 billion.

Market Watch
Positive
Sage, Biogen now plan to submit depression drug candidate to FDA in second half of 2022
12 hours ago

Shares of Sage Therapeutics Inc. SAGE, -8.58% gained 0.5% in premarket trading on Wednesday, the day after the company said it and Biogen Inc. BIIB, -0.59% plan to submit their experimental depression drug to U.S. regulators for approval in the second half of next year. They will also seek approval for zuranolone as a treatment for postpartum depression in the first half of 2023.

Market Watch
Positive
Biogen's stock is up on strong earnings; new Alzheimer's drug had $300,000 in sales in Q3
12 hours ago

Shares of Biogen Inc. BIIB, -0.59% were up 1.8% in premarket trading on Wednesday after the company beat expectations for the third quarter despite lower-than-expected utilization of Aduhelm, its controversial and closely watched new Alzheimer's disease treatment. Biogen had net income of $329.2 million, or $2.22 per share, in the third quarter of 2021, compared with net income of $701.5 million, or $4.47 per share, in the same quarter a year ago.

Loading more news...